Compare CNA & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CNA | ABVX |
|---|---|---|
| Founded | 1853 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 11.9B |
| IPO Year | 1994 | 2022 |
| Metric | CNA | ABVX |
|---|---|---|
| Price | $45.58 | $95.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $131.31 |
| AVG Volume (30 Days) | 529.3K | ★ 1.3M |
| Earning Date | 05-04-2026 | 03-23-2026 |
| Dividend Yield | ★ 8.20% | N/A |
| EPS Growth | ★ 33.24 | N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | ★ $14,989,000,000.00 | N/A |
| Revenue This Year | N/A | $52.14 |
| Revenue Next Year | N/A | $4,132.27 |
| P/E Ratio | $23.30 | ★ N/A |
| Revenue Growth | ★ 5.04 | N/A |
| 52 Week Low | $41.53 | $69.81 |
| 52 Week High | $55.71 | $148.83 |
| Indicator | CNA | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 27.67 | 34.28 |
| Support Level | $45.20 | $74.79 |
| Resistance Level | $49.00 | $130.96 |
| Average True Range (ATR) | 0.93 | 4.47 |
| MACD | -0.17 | -1.17 |
| Stochastic Oscillator | 15.36 | 11.16 |
CNA Financial Corporation (CNAF) is an insurance holding company that provides commercial property and casualty insurance. The company operates under five segments: Specialty, Commercial and International being its core business, and two segments for its non-core businesses, which are Life and Group and Corporate and Other. CNAF, through its segments, provides professional, financial, specialty property, and casualty products to small businesses and medium-scale organizations. It has its business spread across Continental Europe, United Kingdom, and Canada. The majority of the revenues are generated from the Specialty and Commercial segment of the business.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.